Calamos Advisors
NVO

Calamos Advisors’s Novo Nordisk NVO Stock Holding History

Calamos Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-64,800
Closed -$4.47M – 982
2025
Q3 		$4.47M Buy
+64,800
New +$3.79M 0.02% 552
2025
Q2 		– Sell
-95,100
Closed -$8.18M – 969
2025
Q1 		$8.18M Buy
+95,100
New +$7.85M 0.04% 435

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Calamos Advisors's NVO Position: Q1 2026 in Review

Calamos Advisors reduced its Novo Nordisk (NVO) stake by 11% in Q1 2026, selling an estimated $605K and leaving 98,472 shares worth $3.62M. The position accounts for 0.01% of the portfolio, ranked #600.

Calamos Advisors first reported a position in NVO in Q2 2013 and has held it in 30 quarters since. The position peaked at $43.4M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Calamos Advisors held 98,472 shares of Novo Nordisk worth $3.62M as of Q1 2026.
  • Calamos Advisors sold 12,760 Novo Nordisk shares in Q1 2026, an estimated $605K.
  • Novo Nordisk made up 0.01% of Calamos Advisors's portfolio in Q1 2026, its #600 holding.
  • Calamos Advisors first reported a position in Novo Nordisk in Q2 2013 and has held it in 30 quarters since.
  • Calamos Advisors's Novo Nordisk position peaked at $43.4M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.